Deals
Nektar Therapeutics Weighs Options Including Sale
- Biotechnology company is also said to weigh partnerships
- Nektar market value has more than tripled to $15 billion
Biotech Firm Nektar Therapeutics Explores Partnership Options
This article is for subscribers only.
Nektar Therapeutics is exploring options including a potential sale of the $15 billion biotechnology firm, according to people with knowledge of the matter.
The San Francisco-based company could also opt for partnerships and licensing agreements instead of a disposal, said the people, asking not to be identified as the discussions are private. Nektar has attracted interest from larger drugmakers, though some potential suitors are wary of a full takeover because of the high valuation and risks related to its pipeline of experimental drugs, the people said.